RxDoctor Payments Data

Lorie Startup, NP

Family · Carrollton, GANPI 1871112110

Payments from drug & device makers

$3,617in general payments, 2019–2025

Across 204 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$564
  • Esperion Therapeutics, Inc.$550
  • Novartis$509
  • Pfizer$388
  • Merck$342
  • E.r. Squibb & Sons, L.L.C.$214
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,617100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,617 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$23,094
Medicare patients
170
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban283$227,476
EntrestoSacubitril/Valsartan171$136,781
JardianceEmpagliflozin47$48,662
BrilintaTicagrelor55$42,857
XareltoRivaroxaban48$37,417
Repatha SureclickEvolocumab31$28,678
Ranolazine ErRanolazine299$16,717
Ezetimibe202$4,180
Metoprolol Succinate349$3,734
Isosorbide Dinitrate60$2,205
Hydralazine Hcl192$1,951
Potassium Chloride171$1,839
Enoxaparin Sodium27$1,756
Losartan Potassium237$1,559
Amiodarone Hcl123$1,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$388$227,476283 claims
NovartisEntresto$509$136,781171 claims
Boehringer IngelheimJardiance$15$48,66247 claims
AstraZenecaBrilinta$108$42,85755 claims
Johnson & JohnsonXarelto$65$37,41748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Carrollton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →